FPS-ZM1 is primarily utilized in research focused on neurodegenerative diseases, particularly Alzheimer's disease. It functions as a selective inhibitor of the receptor for advanced glycation end products (RAGE), which plays a significant role in inflammation and neuronal damage. By blocking RAGE, FPS-ZM1 helps reduce amyloid-beta accumulation and neuroinflammation, making it a promising candidate for therapeutic studies. Additionally, it is used to explore its potential in mitigating cognitive decline and improving memory functions in preclinical models. Its application extends to investigating the molecular mechanisms underlying RAGE-mediated pathways in various neurological disorders.